CONCORD, Mass., Oct. 15, 2019 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mechanistic modeling, simulation, and analysis to de-risk drug research and development, recently announced their participation in several conference sessions at ACoP10 occurring October 20-24, 2019 in Orlando, FL. They will also present the following posters at the conference.
Monday, October 21st
Tuesday, October 22nd
Wednesday, October 23rd
"We are thrilled to present work that features collaborations with our scientific partners, including Biogen and Pfizer, and internal scientific projects," said John Burke, PhD, Co-founder, President and CEO, Applied BioMath. "These posters demonstrate the value of mechanistic and systems modeling and we are excited to share our science with the attendees at ACoP10."
For more information about Applied BioMath's presence at ACoP10, visit https://www.appliedbiomath.com/acop10.
About Applied BioMath
Founded in 2013, Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their Model-Aided Drug Invention (MADI) approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.
Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.
Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com
SOURCE Applied BioMath, LLC